Bambusa Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)CIK 0002044950Boston, MassachusettsFilings at SEC EDGAR

At a glance

Most recent filing on November 2, 2026 — a conversion by Salvia Investment GmbH on Nov 2, 2026.

We hold 20 Form 4 lines, going back to November 2, 2026.

Insider trades

5 of 20 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 20. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Salvia Investment GmbH 10% owner
160,860 sharesConversion
TradedNov 2, 2026FiledNov 2, 2026
Salvia Investment GmbH 10% owner
1,473,775 sharesConversion
TradedNov 2, 2026FiledNov 2, 2026
Salvia Investment GmbH 10% owner
3,135,066 sharesConversion
TradedNov 2, 2026FiledNov 2, 2026
Salvia Investment GmbH 10% owner
$6,000,000Open-market buy
TradedNov 2, 2026FiledNov 2, 2026
Salvia Investment GmbH 10% owner
—Conversion
TradedNov 2, 2026FiledNov 2, 2026